Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib

Ann Rheum Dis. 2019 Aug;78(8):1135-1138. doi: 10.1136/annrheumdis-2018-214261. Epub 2019 Mar 6.
No abstract available

Keywords: DMARDs (synthetic); rheumatoid arthritis; treatment.

Publication types

  • Letter

MeSH terms

  • Arthritis, Rheumatoid / diagnosis
  • Arthritis, Rheumatoid / drug therapy*
  • Azetidines / therapeutic use*
  • Case-Control Studies
  • Databases, Factual
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Janus Kinase Inhibitors / therapeutic use*
  • Male
  • Patient Safety / statistics & numerical data*
  • Preexisting Condition Coverage / statistics & numerical data*
  • Severity of Illness Index
  • Sulfonamides / therapeutic use*
  • Treatment Outcome

Substances

  • Azetidines
  • Janus Kinase Inhibitors
  • Sulfonamides
  • baricitinib

Associated data

  • ClinicalTrials.gov/NCT01185353
  • ClinicalTrials.gov/NCT01469013
  • ClinicalTrials.gov/NCT00902486
  • ClinicalTrials.gov/NCT01710358
  • ClinicalTrials.gov/NCT01721057